4-((4-(4-Chloro-3-(trifluoromethyl)phenoxy)-3-fluorobenzyl)oxy)-1-methyl-6-morpholinopyrimidin-2(1H)-one

ID: ALA3794054

Chembl Id: CHEMBL3794054

PubChem CID: 121448380

Max Phase: Preclinical

Molecular Formula: C23H20ClF4N3O4

Molecular Weight: 513.88

Molecule Type: Small molecule

Associated Items:

Names and Identifiers

Canonical SMILES:  Cn1c(N2CCOCC2)cc(OCc2ccc(Oc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)nc1=O

Standard InChI:  InChI=1S/C23H20ClF4N3O4/c1-30-21(31-6-8-33-9-7-31)12-20(29-22(30)32)34-13-14-2-5-19(18(25)10-14)35-15-3-4-17(24)16(11-15)23(26,27)28/h2-5,10-12H,6-9,13H2,1H3

Standard InChI Key:  HGMODZYWSFTDMK-UHFFFAOYSA-N

Alternative Forms

  1. Parent:

    ALA3794054

    ---

Associated Targets(Human)

PLA2G7 Tchem LDL-associated phospholipase A2 (1338 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Liver (3974 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Liver (4264 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 513.88Molecular Weight (Monoisotopic): 513.1078AlogP: 4.80#Rotatable Bonds: 6
Polar Surface Area: 65.82Molecular Species: NEUTRALHBA: 7HBD: 0
#RO5 Violations: 1HBA (Lipinski): 7HBD (Lipinski): 0#RO5 Violations (Lipinski): 1
CX Acidic pKa: CX Basic pKa: CX LogP: 4.79CX LogD: 4.79
Aromatic Rings: 3Heavy Atoms: 35QED Weighted: 0.44Np Likeness Score: -1.54

References

1. Chen X, Wang K, Xu W, Ma Q, Chen M, Du L, Mo M, Wang Y, Shen J..  (2016)  Discovery of Potent and Orally Active Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) Inhibitors as a Potential Therapy for Diabetic Macular Edema.,  59  (6): [PMID:26927682] [10.1021/acs.jmedchem.5b01930]

Source